myelodysplastic syndromes

Geron surges after winning first US FDA approval for blood disorder drug
Reuters
Fri, 06/7/24 - 11:14 am
Geron
Rytelo
FDA
myelodysplastic syndromes
Bristol Myers gets key FDA approval for bone marrow disease drug
BioPharma Dive
Wed, 08/30/23 - 09:54 am
Bristol Myers Squibb
FDA
Reblozyl
myelodysplastic syndromes
Bristol Myers data make case for earlier use of bone marrow disease drug
BioPharma Dive
Thu, 05/25/23 - 08:31 pm
Bristol Myers Squibb
Reblozyl
Epogen
myelodysplastic syndromes
clinical trials
After 33 years Geron could have an approved drug
EP Vantage
Wed, 01/4/23 - 09:44 am
Geron
imetelstat
clinical trials
myelodysplastic syndromes
After a ‘breakthrough’ beginning to 2020, little Aprea gets crushed by a PhIII failure
Endpoints
Mon, 12/28/20 - 10:50 am
Aprea Therapeutics
eprenetapopt
clinical trials
myelodysplastic syndromes
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Pharmaceutical Business Review
Wed, 12/4/19 - 10:34 am
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
myelodysplastic syndromes
Aprea Therapeutics Files for $86 Million IPO
CP Wire
Mon, 09/9/19 - 09:58 am
Aprea Therapeutics
myelodysplastic syndromes
IPOs
Aprea Therapeutics Files for $86 Million IPO
Mon, 09/9/19 - 09:33 am
Aprea Therapeutics
myelodysplastic syndromes
Wockhardt receives US FDA approval for cancer drug
Pharmaceutical Business Review
Fri, 04/12/19 - 10:09 am
Wockhardt
decitabine
FDA
generics
Otsuka
Dacogen
myelodysplastic syndromes
FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes
Yahoo
Mon, 12/7/15 - 10:34 am
FDA
fast track
luspatercept
myelodysplastic syndromes
Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
Yahoo
Sun, 12/6/15 - 10:16 am
Celgene
Acceleron
myelodysplastic syndromes
MDS
luspatercept
Onconova hammered after top drug rigosertib flunks key PhIII study
Fierce Biotech
Thu, 02/20/14 - 05:33 pm
Onconova
Rigosertib
myelodysplastic syndromes
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH
Yahoo/BusinessWire
Sun, 12/8/13 - 12:07 pm
CC-486
Celgene
myelodysplastic syndromes
Acceleron Receives Two FDA Orphan Designations for ACE-536
Yahoo
Tue, 03/26/13 - 10:34 am
FDA
orphan drugs
ACE-536
Acceleron
beta-thalassemia
myelodysplastic syndromes